

Product Data Sheet

Product Name: PD173952

Cat. No.: GC72924

Chemical Properties

Cas. No. 305820-75-1


Formula $C_{24}H_{21}Cl_2N_5O_2$ M.Wt 482.36

Solubility DMSO : 16.67 mg/mL (34.56 mM; ultrasonic and warming and heat to 60°C) Storage -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Background

PD173952 is a tyrosine kinases inhibitor with IC₅₀s of 0.3, 1.7 and 6.6 nM against Lyn, Abl and Csk, respectively. PD173952 is also a potent Myt1 kinase inhibitor with a K_i of 8.1 nM. PD173952 induces apoptosis.

PD173952 (0-1000 nM; 12 h) inhibits tyrosine phosphorylation of p210^{Bcr-Abl} and CrkL in K562 cells in a concentration-dependent manner[1]. PD173952 (0.5 μM; 1-4 days) inhibits K562 cell

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

viability[1].PD173952 (0.5 μ M; 24 and 48 h) induces apoptosis of K562 and MEG-01 cells[1].

References:

- [1]. Dorsey JF, et al. Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. *Leukemia*. 2002 Sep;16(9):1589-95.
- [2]. Wichapong K, et al. Application of docking and QM/MM-GBSA rescoring to screen for novel Myt1 kinase inhibitors. *J Chem Inf Model*. 2014 Mar 24;54(3):881-93.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA